Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Report Date: September 10, 2026
Principal Executive Office: Marseille, France
Context: This filing serves as a cover document for a press release (Exhibit 99.1) dated September 10, 2026. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text contains only the cover page and signature block of the Form 6-K. It does not include the content of the referenced press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as no financial data or operational updates are included in the excerpt.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details regarding unusual items. These details are presumably contained within Exhibit 99.1 (Press Release), which is not included in the input content.
Investor Verification Checklist
- Verify the specific content of the press release (Exhibit 99.1) referenced in this filing to understand the material event triggering the report.
- Confirm whether the press release contains updated clinical trial data, regulatory milestones, or financial guidance.
- Review the company's most recent Form 20-F for the latest audited financial statements, as this 6-K does not provide them.